According to the latest report by IMARC Group, titled “Radiopharmaceuticals Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” the global radiopharmaceuticals market reached a value of US$ 4.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2027, exhibiting a CAGR of 6.76% during 2022-2027. Radiopharmaceuticals refer to radioisotopes bound to biological molecules that can target specific tissues, cells or organs in a human body. These radioactive drugs can be differentiated into four categories, namely, radiopharmaceutical preparation, kit for radiopharmaceutical preparation, radionuclide generator, and radiopharmaceutical precursor. These medicines help to diagnose various ailments, including abscess and infection, blood vessel diseases, bone marrow diseases, cancer and tumors, colorectal disease, and kidney, lungs and liver diseases.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally–our estimates about the latest market trends and forecast values after considering the impact of this pandemic.
Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/radiopharmaceuticals-market/requestsample
Global Radiopharmaceuticals Market Trends:
The rising availability and acceptance of several cancer-specific targeted therapies and diagnostic tests is majorly fueling the global radiopharmaceuticals market. It is further supported by the increasing prevalence of target conditions across the globe. Additionally, the rising utilization of radiopharmaceuticals in neurological applications is contributing to the market growth. Rapid advancements in the diagnostics sector, the presence of favorable regulations, and increasing investments in research and development (R&D) activities to assess the side effects of therapies are other factors influencing the market growth positively.
Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: https://www.imarcgroup.com/radiopharmaceuticals-market
Global Radiopharmaceuticals Market 2022-2027 Analysis and Segmentation:
Competitive Landscape with Key Player:
- Advanced Accelerator Applications (Novartis AG)
- Bayer AG
- Bracco S.p.A.
- Cardinal Health Inc.
- Curium Pharma
- General Electric Company
- IBA RadioPharma Solutions
- Jubilant Pharma Limited
- Lantheus Medical Imaging Inc
- Nordion Inc. (Sotera Health)
- NTP Radioisotopes SOC Ltd
- PharmaLogic Holdings Corp.
- Siemens AG.
Breakup by Product Type:
- Diagnostic Nuclear Medicine
- Therapeutic Nuclear Medicine
Breakup by Application:
Breakup by End Use:
- Hospitals and Clinics
- Research Institutes
- Diagnostic Centers
Breakup by Region:
- North America (United States, Canada)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key Highlights of the Report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800